Callbo, Paliz Nordlöf http://orcid.org/0000-0002-4308-3745
Junus, Katja
Gabrysch, Katja
Bergman, Lina
Poromaa, Inger Sundström
Lager, Susanne
Wikström, Anna-Karin
Funding for this research was provided by:
Region Uppsala (LUL-915281)
Svenska Sällskapet för Medicinsk Forskning (P180029)
Swedish clinical research agreement (ALFGBG942685)
Vetenskapsrådet (2020-01026, 2020-01640)
Uppsala University
Article History
Received: 13 May 2023
Accepted: 19 December 2023
First Online: 22 January 2024
Declarations
:
: The study was approved by the Regional Ethical Review Board in Uppsala, Sweden (Dnr: 2007/181, Dnr: 2018/251). All research was performed in accordance with relevant national and international guidelines.
: The procedures of this study included written informed consent from participating women at the time of the blood sample collection.
: The authors of this manuscript have given their consent for submission and publication of this study.
: AKW and LB: Board members and responsible for the biobank in the IMPACT study, in which PlGF reagents were donated by Roche, Perkin Elmer, and Thermo Fischer. LB: Course leader for the course in Preeclampsia in Sweden with sponsorship by Thermo Fischer and Roche. Obtained reimbursement for lecture by iLab Medical and reimbursement from Homburg and Partner as expert opinion. Board member in intervention trials in which the trial drug has been donated by Merck.The remaining authors have no competing interests to declare that are relevant to the content of this article.